Almost half of doctors bar their doors to pharma sales reps some way, somehow. What with all the talk about rep access to physicians, that state of things may seem quote-unquote normal. But it's not. Just 6 years ago, the numbers were quite different.
It started in 2011 with just a handful of drugs. CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. Now, CVS' excluded list comprises almost 100 drugs and related products.
When do rising drug prices not equal rising sales? When payers step in to control costs--and that's exactly what they've been doing.
The FDA may be having problems handing down its social media commandments. But it's playing enforcer just the same.
Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.
The editors at FiercePharma in the last 18 months have found ourselves writing a fair number of stories about animal health operations. Many of the companies we cover have animal health units and the success, or lack thereof, for those is a big deal for these companies and their investors.
Doctors aren't the only ones to fall prey to free lunches and fuzzy promotional talks. Medical students who spend more time with& pharma reps are more likely to dole out brand-name products, and less likely to rely on evidence when choosing which drugs to use, Medscape reports.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.
I'm not a doctor, but I play one on TV. That approach has put pharma in the doghouse before. But now, here's a new question. What about, "I'm not a patient, but I play one in a promo campaign for doctors"?
It's a tale of two statin drugs and their attempts to keep market share--or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay discount program, and this time, it applies to patients covered via certain U.S. government programs.